Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA) – HC Wainwright cut their Q1 2026 earnings estimates for shares of Vera Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst A. He now expects that the company will earn ($1.35) per share for the quarter, down from their prior estimate of ($0.98). HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q2 2026 earnings at ($1.31) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($4.84) EPS, FY2027 earnings at ($1.53) EPS, FY2028 earnings at $2.04 EPS, FY2029 earnings at $8.43 EPS and FY2030 earnings at $9.88 EPS.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, December 19th. The Goldman Sachs Group raised their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Wedbush boosted their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Finally, Bank of America upped their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $80.80.

Vera Therapeutics Trading Up 0.9%

Shares of VERA stock opened at $39.65 on Thursday. The stock has a market capitalization of $2.78 billion, a PE ratio of -8.51 and a beta of 1.17. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $56.05. The business has a 50-day moving average of $45.45 and a 200 day moving average of $35.98. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period last year, the company earned ($0.72) EPS.

Insider Activity

In related news, CFO Sean Grant sold 4,949 shares of Vera Therapeutics stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer directly owned 114,181 shares in the company, valued at $4,793,318.38. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marshall Fordyce sold 16,925 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $710,511.50. Following the completion of the transaction, the chief executive officer owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. This trade represents a 6.18% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 33,490 shares of company stock worth $1,405,910. Company insiders own 16.30% of the company’s stock.

Institutional Trading of Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares in the last quarter. Optimize Financial Inc lifted its holdings in shares of Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after purchasing an additional 256 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in shares of Vera Therapeutics by 5.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after buying an additional 424 shares during the last quarter. Finally, Invesco Ltd. increased its position in Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after buying an additional 550 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $110 price target and raised their FY2029 and FY2030 EPS forecasts (FY2029: $8.43; FY2030: $9.88), signaling conviction in Vera’s longer‑term commercial or pipeline potential. Article Title
• Neutral Sentiment: The report lays out a multi‑year recovery profile (FY2027–FY2028–FY2029) showing a transition from losses to substantial upside — this creates a binary trade: near‑term execution risk vs. sizable longer‑term reward. Reference: company analyst note summary. VERA on MarketBeat
• Negative Sentiment: HC Wainwright materially cut near‑term estimates: Q1–Q4 2026 EPS were revised lower (now roughly -$1.35, -$1.31, -$1.26, -$0.93 respectively) and FY2026 EPS dropped to -$4.84 (from -$3.18 previously). Those downgrades increase the risk of near‑term earnings misses and likely pressured the stock today. VERA on MarketBeat

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.